基于氨酸聚胺的新型合成纳米颗粒的临床前评估,以改善向肺部输送
Eman Zmaily Dahmash1, Nour Radwan Achkar2, Dalia Khalil Ali3
1Department of Chemistry and Pharmaceutical Sciences, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, KT1 2EE, UK. e.dahmash@kingston.ac.uk.
Scientific reports
|April 29, 2024
概括
纳米技术通过创建统一,可重复的固定剂量组合吸入器来增强喘治疗. 新型纳米颗粒改善了药物向肺部的输送,为有效管理喘提供了优越的替代方案.
科学领域:
- 制药纳米技术 制药纳米技术
- 药物输送系统 药物输送系统
- 材料科学 材料科学 材料科学
背景情况:
- 单个吸入器中的固定剂量组合 (FDC) 改善了患者对呼吸系统疾病的遵守.
- 为FDCs开发统一和可重复的干粉吸入器 (DPI) 提出了重要的配方挑战.
研究的目的:
- 开发一种基于纳米技术的FDC DPI,使用酸 (FP) 和沙米特醇酸 (SAL) 治疗喘.
- 解决FDCDPI中的配方统一性和可重复性问题.
主要方法:
- 药物装载纳米颗粒的制备,使用一种新型的基于氨酸的聚胺 (聚胺) 通过单步界面聚合.
- 包括内容统一性,粒子大小分析 (PSA),FTIR,TEM,DSC,XRD和空气动力学性能评估在内的全面表征.
- 在体外和体内对优化纳米粒子配方的评估.
主要成果:
- 高药物捕获效率 (>90%) 在优化的纳米粒子配方中实现.
- 与市场上销售的产品相比,其优越的空气动力学性能 (排放剂量,微粒分数,可呼吸剂量).
- 在体内小鼠研究中,可重复的FP和SAL向肺部输送,FP水平超过了市场配方.
结论:
- 通过一阶段工艺制备的新型FDC FP/SAL纳米颗粒显示出卓越的性能.
- 这种纳米技术方法为喘管理提供了一种具有成本效益和效率的方法.
- 开发的纳米粒子增强了FDC DPIs的药物输送和可重复性.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


